Customize
Quick Links
Specialties

Accreditation/Credit Designation

Physicians' Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians' Education Resource®, LLC, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgment of Commercial Support

This activity is supported by educational grants from Bristol-Myers Squibb and Incyte Corporation.

Cancer Summaries and Commentaries™: Report from San Diego on Advances in the Treatment of GvHD


Release Date: December 30, 2018
Expiration Date: December 30, 2019
Media: Internet - based

Activity Overview

This online activity is designed to update physicians on data presented at the American Hematology Association (ASH) Annual Meeting, held in December 2018 in San Diego, CA. PER’s Cancer Summaries and Commentaries™: Report from San Diego on Advances in the Treatment of Graft-Versus-Host Disease online CME activity facilitates critical assessment and clinical integration of new evidence when appropriate. The activity reviews 7 abstracts with some of the most compelling and clinically relevant graft-versus-host disease (GvHD) presentations from the meeting. For each abstract, a short summary of key clinical data is accompanied by expert perspectives that provide insight into how clinicians can apply these findings to their clinical practice to improve patient care.

Benefits of Participation:

  • Learn about emerging treatments for the management of GvHD
  • Hear about biomarkers that may identify those at high risk for GvHD
  • Learn how to manage GvHD in patients with hematologic malignancies
  • Explore future directions for the prevention of GvHD
  • Be informed about recent clinical trials and their impact on clinical practice decisions

Acknowledgement of Commercial Support

This activity is supported by educational grants from Bristol-Myers Squibb and Incyte Corporation.

Instructions for This Activity and Receiving Credit

  • You will need to log in to participate in the activity.
  • Each presentation may contain an interactive question(s). You may move forward through the presentation; however, you may not go back to change answers or review audio files/content until you finish the presentation.
  • At the end of the activity, educational content/audio files will be available for your reference.
  • In order to receive a CME certificate, you must complete the activity.
  • Complete the Posttest and pass with a score of 70% or higher, complete the Evaluation, and then click on “Request for Credit.” You may immediately download a CME certificate upon completion of these steps.


Target Audience

This activity is directed toward medical oncologists and hematologists who treat patients with hematologic malignancies. Fellows, nurses, nurse practitioners, physician assistants, and other healthcare professionals interested in the management of patients with hematologic malignancies are also invited to participate.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

  • Summarize GvHD biology, pathogenesis, and evidence that best informs clinical practice to manage symptoms
  • Explain recent clinical trial results regarding novel compounds and strategies for patients with acute and chronic GvHD
  • Place presented trial evidence into the context of evolving treatment paradigms and strategies in the management of patients with GvHD resulting from treatment for hematologic malignancies

Faculty, Staff, and Planners' Disclosures

Faculty

James L. M. Ferrara, MD, DSc
Ward-Coleman Chair in Cancer Medicine
Professor of Medicine and Pediatrics
Director, Hematologic Malignancies Translational Research Center
Icahn School of Medicine at Mount Sinai
New York City, NY

Disclosures: Consultant: ViraCor, Incyte, Kamada, Mallinckrodt; Intellectual Property: Biomarkers for acute GvHD

Mark A. Schroeder, MD
Associate Professor of Medicine
Washington University School of Medicine
Division of Oncology, Section of Stem Cell Transplantation
St. Louis, MO
 

Disclosures: Consultant: Incyte, Amgen, Sanofi/Genzyme, Pfizer, Flatiron; Speaker’s Bureau: Merck, Takeda

The staff of PER® have no relevant financial relationships with commercial interests to disclose.

Disclosure Policy and Resolution of Conflicts of Interest (COI)

As a sponsor accredited by the ACCME, it is the policy of PER® to ensure fair balance, independence, objectivity, and scientific rigor in all of its CME activities. In compliance with ACCME guidelines, PER® requires everyone who is in a position to control the content of a CME activity to disclose all relevant financial relationships with commercial interests. The ACCME defines “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that creates a COI.

Additionally, PER® is required by ACCME to resolve all COI. PER® has identified and resolved all COI prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This CME activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME activity is for continuing medical and nursing education purposes only, and is not meant to substitute for the independent clinical judgment of a physician relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER®.







Become a Member

Forgot Password?
Filter By